# US Genomics Market

> United States Genomics Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 13.1%
- **2024:** $ 16.5 Billion
- **2025:** $ 18.66 Billion
- **2035:** $ 63.9 Billion
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), BGI Genomics (CN), Qiagen (DE), PerkinElmer (US), Eurofins Scientific (LU)

**Report ID:** MRFR/HC/14351-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-genomics-market-15878

---

## Market Summary

## US Genomics Market Highlighted Trends & Dynamics

Leading the way in revolutionary developments in healthcare, research, and tailored therapy is the US genomics market. The study of an individual's whole DNA sequence, or genomics, is essential to comprehending genetic differences, inherited features, and disease risk.

The quickening speed of genomic research and its use in clinical settings is one of the main factors propelling this market. After the Human Genome Project was finished in 2003, tremendous progress was made toward deciphering the human genome, which opened the door for innovations in genomics applications and research.

The US Genomics Market is characterized by a heterogeneous set of competitors, comprising diagnostic laboratories, academic organizations, and biotechnology businesses. Partnerships amongst genomics researchers, medical professionals, and tech companies support continuing advancements that propel the market's development. The area has undergone a revolution thanks to genomic technologies like next-generation sequencing (NGS), which have made it possible to quickly and affordably sequence complete genomes and to better comprehend genetic variants.

Bioinformatics and artificial intelligence (AI) are being integrated by the industry as a solution to difficulties such as ethical considerations and the interpretation of complicated genetic data. Large genomic datasets may be analyzed and interpreted with the use of bioinformatics tools, which enable academics and medical professionals to get insightful knowledge. Strong ethical frameworks and legal requirements are crucial given the ethical issues surrounding genomics, which include privacy issues and the appropriate use of genetic data.

Many fields, such as clinical diagnostics, medication development, and precision medicine, use genomics extensively. Genomic testing is used in clinical diagnostics to identify genetic markers linked to illnesses, allowing for early detection, risk assessment, and customized treatment regimens. Genomic analysis is an essential component of drug development as it helps identify targets, comprehend disease processes, and create customized targeted treatments based on the genetic profiles of particular patients. Genomic data is a key component of precision medicine, a paradigm that customizes medical care to each patient's unique traits. This allows for more individualized and successful healthcare interventions.

Even with this encouraging trend, there are still issues facing the genomics market, including the cost of genomic testing, differences in access to genetic services, and the requirement for thorough education. In order to address these issues, efforts are being made to improve genetic awareness among healthcare professionals and the general public, as well as to advocate for insurance coverage of genomic testing and research into cost-effective sequencing technology.

Growing applications, including multi-omics techniques (genomics, transcriptomics, proteomics, etc.), and moving toward precision health are becoming more and more important as the US genome market develops. Researchers and medical professionals may better understand biological systems and create tailored therapies by utilizing multi-omics techniques, which help to simplify complicated disorders. The future of the genomics market is shaped by the cooperative efforts of genomics researchers, pharmaceutical firms, and healthcare institutions, which position the market as a catalyst for the advancement of precise and customized healthcare techniques.

## Market Drivers

### Expansion of Genomic Research Funding

The US government and private sector are significantly increasing funding for genomic research, which is a key driver of the genomics market. Federal agencies, such as the National Institutes of Health (NIH), have allocated billions of dollars to genomics research initiatives, aiming to advance understanding of genetic diseases and develop innovative therapies. In 2025, funding for genomics research is anticipated to surpass $5 billion, reflecting a commitment to enhancing public health through genomic science. This influx of capital not only supports academic research but also stimulates collaboration between public and private entities, fostering innovation and accelerating the translation of genomic discoveries into clinical applications.

### Increasing Demand for Genetic Testing

The growing awareness of genetic testing among consumers is driving the genomics market in the US. Individuals are increasingly seeking insights into their genetic predispositions to various health conditions, which has led to a surge in demand for genetic testing services. According to recent estimates, the genetic testing market is projected to reach approximately $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 11%. This trend is further fueled by advancements in technology that make genetic testing more accessible and affordable. As healthcare providers incorporate genetic testing into routine care, the genomics market is likely to expand, offering new opportunities for innovation and service delivery.

### Rising Prevalence of Genetic Disorders

The increasing prevalence of genetic disorders in the US is propelling the growth of the genomics market. Conditions such as cystic fibrosis, sickle cell disease, and various hereditary cancers are becoming more recognized, leading to heightened demand for genetic testing and counseling services. It is estimated that approximately 1 in 10 individuals in the US is affected by a genetic disorder, which underscores the necessity for effective diagnostic tools and treatment options. As healthcare providers seek to address these challenges, the genomics market is likely to expand, offering innovative solutions that cater to the needs of patients and healthcare systems alike.

### Integration of Genomics in Drug Development

The integration of genomics into drug development processes is reshaping the landscape of the genomics market. Pharmaceutical companies are increasingly leveraging genomic data to identify potential drug targets and develop personalized therapies. This shift is evidenced by the fact that over 60% of new drug approvals in recent years have involved some form of genomic data analysis. The ability to tailor treatments based on genetic profiles not only enhances efficacy but also reduces adverse effects, thereby improving patient outcomes. As the industry continues to embrace genomics, the market is expected to witness substantial growth, with investments in genomic research and development projected to exceed $20 billion by 2025.

### Technological Advancements in Sequencing Methods

Technological advancements in sequencing methods are revolutionizing the genomics market. Innovations such as next-generation sequencing (NGS) have dramatically reduced the cost and time required for genomic analysis, making it more accessible to researchers and clinicians. The cost of sequencing a human genome has plummeted from over $100 million in the early 2000s to less than $1,000 today, facilitating widespread adoption. This democratization of genomic data is expected to drive market growth, as more institutions and laboratories invest in sequencing technologies. By 2026, the market for sequencing technologies is projected to reach $15 billion, indicating a robust demand for these advanced methodologies.

## Future Outlook

The [Genomics Market](https://www.marketresearchfuture.com/reports/genomics-market-12283) is projected to grow at 13.1% CAGR from 2025 to 2035, driven by advancements in technology, increased demand for personalized medicine, and rising investments in research.

**New opportunities:**

- Development of AI-driven genomic analysis platforms Expansion of direct-to-consumer genetic testing services Integration of genomics in precision agriculture solutions

By 2035, the genomics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Clinical Diagnostics (Largest) vs. Personalized Medicine (Fastest-Growing)

In the US genomics market, the application segment showcases a dynamic distribution of market share among key values: Drug Discovery, Clinical Diagnostics, Personalized Medicine, and Genetic Testing. Clinical Diagnostics occupies the largest share, driven by a surge in demand for accurate and timely diagnoses. Meanwhile, Personalized Medicine is rapidly gaining traction, supported by advancements in genomics and a growing focus on tailored therapeutic approaches, appealing to both healthcare providers and patients alike.

The growth trends for these segments reveal strong drivers propelling the market forward. Clinical Diagnostics benefits from the integration of genomic data into routine testing, enhancing diagnostic precision. On the other hand, Personalized Medicine is recognized as the fastest-growing segment, propelled by increased investment in research, innovative technologies, and a rising preference for customized healthcare solutions. Consumers and providers are increasingly advocating for treatments tailored to individual genetic profiles, indicating bright prospects for this segment.

Clinical Diagnostics (Dominant) vs. Personalized Medicine (Emerging)

Clinical Diagnostics stands as the dominant force in the application segment, largely due to its crucial role in patient care and disease management. Providing essential insights into patient health, it leverages genomic data to improve accuracy in disease detection and monitoring. The market is characterized by a wide array of testing options, including advanced sequencing technologies and biomarkers, catering to various health conditions. Conversely, Personalized Medicine represents an emerging paradigm, emphasizing individualized treatment plans based on genetic makeup. This segment is increasingly recognized for its potential to enhance therapeutic efficacy and minimize adverse effects, leveraging innovations in genomics to target specific patient profiles and conditions. Together, they highlight the evolving landscape of healthcare driven by genomic advancements.

### By Technology: Sequencing (Largest) vs. CRISPR (Fastest-Growing)

In the US genomics market, Sequencing holds the largest market share among the technology segment values, driven by its extensive applications in research and clinical settings. Microarray and PCR also capture significant portions of the market, catering to specific analytical and diagnostic needs. Each of these technologies serves a unique purpose, factoring into the overall distribution of market share in this competitive field.

Looking ahead, the growth trends indicate that CRISPR is the fastest-growing segment, propelled by advancements in genome editing techniques and increasing investments in research and development. As researchers explore its potential in various therapeutic applications, the demand for CRISPR technology is expected to rise sharply, reshaping the dynamics within the technology segment of the market.

Technology: Sequencing (Dominant) vs. CRISPR (Emerging)

Sequencing stands out as the dominant technology in the US genomics market, characterized by its high accuracy and ability to process vast amounts of genetic data. It is extensively utilized across diverse fields such as personalized medicine, oncology, and genetic research, making it a preferred choice for many genomic applications. In contrast, CRISPR is emerging as a revolutionary force, known for its efficiency in gene editing and modification. Its rapid adoption in research and clinical trials highlights its transformative potential in therapeutic development. While Sequencing is established and reliable, CRISPR's innovative platform is expected to gain traction, driven by its ability to provide precise genetic solutions and hit specific targets in genomics.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US genomics market, hospitals capture a significant share of the end-use segment, driven primarily by their expanding genomic services and the integration of genomics into routine patient care. Diagnostic laboratories also hold a substantial market share, but their role is increasingly becoming critical as they adapt to the burgeoning demand for personalized medicine and faster, more accurate testing. Research institutes and pharmaceutical companies, while important, account for a lesser portion of the overall market share at present.

Growth trends indicate that diagnostic laboratories are positioned to experience the fastest growth within the segment, fueled by advancements in genomic technologies and the rising emphasis on preventive healthcare. Additionally, hospitals continue to expand their genomic capabilities, which propels their dominance. Collaboration between research institutes and pharmaceutical companies further enhances innovation and accelerates breakthroughs in genomics, contributing positively to market dynamics.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals play a dominant role in the US genomics market, leveraging advanced technologies and resources to offer a wide range of genomic testing and counseling services to patients. This trend is further supported by increased investment in genomic research and integration into the healthcare framework. Diagnostic laboratories, while considered emerging in this context, are rapidly adapting to the evolving landscape and are increasingly essential to meet the growing demand for comprehensive genetic testing. Their focus on innovation and efficiency aligns with the broader trend towards personalized medicine, establishing them as key players in the genomics ecosystem while complementing the services provided by hospitals.

## Competitive Benchmarking

The US genomics market exhibits a dynamic competitive landscape characterized by rapid technological advancements and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Roche (CH) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its sequencing technologies, while Thermo Fisher Scientific (US) emphasizes its comprehensive portfolio of genomic solutions. Roche (CH) is strategically investing in diagnostics and therapeutics, indicating a shift towards integrated healthcare solutions. Collectively, these strategies foster a competitive environment that prioritizes innovation and collaboration. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Illumina (US) and Thermo Fisher Scientific (US) suggests a trend towards consolidation, as these firms seek to leverage economies of scale and broaden their service offerings. In October 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to enhance genomic testing capabilities. This collaboration aims to integrate advanced sequencing technologies into routine clinical practice, potentially revolutionizing patient care. The strategic importance of this partnership lies in its potential to increase accessibility to genomic data, thereby facilitating personalized treatment plans and improving patient outcomes. In September 2025, Thermo Fisher Scientific (US) launched a new line of genomic analysis tools designed to streamline research workflows. This product introduction is significant as it addresses the growing demand for efficient and accurate genomic analysis in both academic and clinical settings. By enhancing its product offerings, Thermo Fisher Scientific (US) positions itself as a leader in the genomics space, catering to the evolving needs of researchers and healthcare professionals. In August 2025, Roche (CH) expanded its portfolio by acquiring a biotech firm specializing in CRISPR technology. This acquisition is pivotal as it not only strengthens Roche's capabilities in gene editing but also aligns with the increasing focus on precision medicine. The integration of CRISPR technology into Roche's offerings could lead to groundbreaking advancements in therapeutic development, further solidifying its competitive edge. As of November 2025, current trends in the genomics market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in genomic research. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and adaptability in a rapidly changing market.

## Report Scope

| MARKET SIZE 2024 | 16.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 18.66(USD Billion) |
| MARKET SIZE 2035 | 63.9(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.1% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), BGI Genomics (CN), Qiagen (DE), PerkinElmer (US), Eurofins Scientific (LU) |
| Segments Covered | Application, Technology, End Use |
| Key Market Opportunities | Advancements in personalized medicine drive growth in the genomics market. |
| Key Market Dynamics | Technological advancements drive innovation and competition in the genomics market, reshaping research and clinical applications. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US genomics market in 2024?**
A: The overall market valuation was $16.5 Billion in 2024.

**Q: What is the projected market valuation for the US genomics market by 2035?**
A: The projected valuation for 2035 is $63.9 Billion.

**Q: What is the expected CAGR for the US genomics market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US genomics market during the forecast period 2025 - 2035 is 13.1%.

**Q: Which companies are considered key players in the US genomics market?**
A: Key players in the market include Illumina, Thermo Fisher Scientific, Roche, Agilent Technologies, BGI Genomics, Qiagen, PerkinElmer, and Eurofins Scientific.

**Q: What are the main application segments in the US genomics market?**
A: The main application segments include Drug Discovery, Clinical Diagnostics, Personalized Medicine, and Genetic Testing.

**Q: What was the market size for Clinical Diagnostics in 2024?**
A: The market size for Clinical Diagnostics was $5.0 Billion in 2024.

**Q: What is the projected market size for Genetic Testing by 2035?**
A: The projected market size for Genetic Testing by 2035 is $19.4 Billion.

**Q: Which technology segment is expected to grow significantly in the US genomics market?**
A: The Sequencing technology segment is expected to grow significantly, with a projected size of $20.0 Billion by 2035.

**Q: What is the market size for Pharmaceutical Companies in 2024?**
A: The market size for Pharmaceutical Companies was $5.6 Billion in 2024.

**Q: What is the projected market size for Diagnostic Laboratories by 2035?**
A: The projected market size for Diagnostic Laboratories by 2035 is $15.5 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-genomics-market-15878*